Hims & Hers Health将推出司美格鲁肽仿制药,进军加拿大市场

老虎资讯综合
15 Jul

周一,Hims & Hers Health股价走高,盘中涨超7%。消息面上,该公司宣布,随着司美格鲁肽在加拿大的专利明年1月到期,其将顺势推出仿制药抢占市场。该公司表示,加拿大近三分之二的成年人存在超重或肥胖问题,但由于费用和供应限制,获得治疗方案的机会仍然有限。

虽然没有透露具体定价,公司在公告中比较称,没有临床支持的品牌司美格鲁肽每月费用超过200加元,而提供全天候执业医师支持的仿制药价格将“大幅降低”,且“有望持续下降”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10